South Korea Non-Alcoholic Steatohepatitis Treatment Market 2023 by Company, Regions, Type and Application, Forecast to 2030

Report ID: IBI1447047 | Category: Medical Care | Pages: 132 | Format: PDF | Published Date: June 27,2023

Request Sample Enquiry before buying Ask For Discount

Single User-$3550.00 Multi User-$4550.00

Report Description
View Table of Contents

Report Summary

Nonalcoholic steatohepatitis (NASH) is inflammation of your liver caused by excess fat cells in it (fatty liver disease). Chronic inflammation causes progressive liver damage. NASH resembles hepatitis caused by alcohol use, but it stems from something else.
The Non-Alcoholic Steatohepatitis Treatment market report provides a detailed analysis of South Korea market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and South Korea market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The South Korea Non-Alcoholic Steatohepatitis Treatment market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
The Non-Alcoholic Steatohepatitis Treatment market in the USA. is estimated at USD million in 2022, which currently accounts for a % share in the South Korea market. China, the world`s second largest economy, is estimated at USD million in 2022 and holds a % percent.
Hospital Pharmacies occupied for % of the Non-Alcoholic Steatohepatitis Treatment South Korea market in 2022, and it is projected to value USD million by 2030, growing at a % CAGR in next six years. In terms of product type, Vitamin E and Pioglitazone segment is altered to a % CAGR between 2022 and 2030.
South Korea key companies of Non-Alcoholic Steatohepatitis Treatment include Intercept Pharmaceuticals, Galmed Pharmaceuticals, Inventiva Pharma, AbbVie Inc. and Galectin Therapeutics Inc., etc. In terms of revenue, the South Korea top four players hold a share over % in 2022.
Key Features of This Report:
This report provides in-depth analysis of the South Korea Non-Alcoholic Steatohepatitis Treatment market, and provides market size and CAGR for the history and forecast period (2017-2022, 2023-2030), considering 2022 as the base year.
Main Non-Alcoholic Steatohepatitis Treatment companies’ industry ranking, revenue, and market share analysis. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This reports profiles key players in the South Korea Non-Alcoholic Steatohepatitis Treatment market based on the following parameters – headquarters, products portfolio, Non-Alcoholic Steatohepatitis Treatment revenue and gross margin, recent developments.
Evaluation and forecast the Non-Alcoholic Steatohepatitis Treatment market size, projected growth trends, and corresponding market share analysis by type, by application and by region. It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
Highlights of the current market scenario, recent information, latest developments, and factors impacting the growth of the market
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Market segmentation
Non-Alcoholic Steatohepatitis Treatment market is split by Type and by Application. For the period 2017-2030, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of revenue. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type (2017-2030; USD Million)
Vitamin E and Pioglitazone
Obeticholic Acid (OCA)
Lanifibranor
Semaglutide
Resmetirom
Aramchol
Cenicriviroc
Others
Market segment by Application (2017-2030; USD Million)
Hospital Pharmacies
Retail & Specialty Pharmacies
Others
The key market players for South Korea Non-Alcoholic Steatohepatitis Treatment market are listed below:
Intercept Pharmaceuticals
Galmed Pharmaceuticals
Inventiva Pharma
AbbVie Inc.
Galectin Therapeutics Inc.
Madrigal Pharmaceuticals
NGM Biopharmaceuticals Inc.
Novo Nordisk A/S
Bristol Myers Squibb
Gilead Sciences Inc.
Region Segment (2017-2030; USD Million)
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Non-Alcoholic Steatohepatitis Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Non-Alcoholic Steatohepatitis Treatment, with revenue, gross margin and South Korea market share of Non-Alcoholic Steatohepatitis Treatment from 2019 to 2022.
Chapter 3, the Non-Alcoholic Steatohepatitis Treatment competitive situation, revenue and South Korea market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Non-Alcoholic Steatohepatitis Treatment market forecast, by regions, type and application, with revenue, from 2023 to 2030.
Chapter 11 and 12, to describe Non-Alcoholic Steatohepatitis Treatment research findings and conclusion, appendix and data source.

1 Market Overview
    1.1 Product Overview and Scope of Non-Alcoholic Steatohepatitis Treatment
    1.2 Classification of Non-Alcoholic Steatohepatitis Treatment by Type
        1.2.1 Overview: South Korea Non-Alcoholic Steatohepatitis Treatment Market Size by Type: 2017 Versus 2022 Versus 2030
        1.2.2 South Korea Non-Alcoholic Steatohepatitis Treatment Revenue Market Share by Type in 2022
        1.2.3 Vitamin E and Pioglitazone
        1.2.4 Obeticholic Acid (OCA)
        1.2.5 Lanifibranor
        1.2.6 Semaglutide
        1.2.7 Resmetirom
        1.2.8 Aramchol
        1.2.9 Cenicriviroc
        1.2.10 Others
    1.3 South Korea Non-Alcoholic Steatohepatitis Treatment Market by Application
        1.3.1 Overview: South Korea Non-Alcoholic Steatohepatitis Treatment Market Size by Application: 2017 Versus 2022 Versus 2030
        1.3.2 Hospital Pharmacies
        1.3.3 Retail & Specialty Pharmacies
        1.3.4 Others
    1.4 South Korea Non-Alcoholic Steatohepatitis Treatment Market Size & Forecast
    1.5 South Korea Non-Alcoholic Steatohepatitis Treatment Market Size and Forecast by Region
        1.5.1 South Korea Non-Alcoholic Steatohepatitis Treatment Market Size by Region: 2017 VS 2022 VS 2030
        1.5.2 South Korea Non-Alcoholic Steatohepatitis Treatment Market Size by Region, (2017-2022)
        1.5.3 North America Non-Alcoholic Steatohepatitis Treatment Market Size and Prospect (2017-2030)
        1.5.4 Europe Non-Alcoholic Steatohepatitis Treatment Market Size and Prospect (2017-2030)
        1.5.5 Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market Size and Prospect (2017-2030)
        1.5.6 South America Non-Alcoholic Steatohepatitis Treatment Market Size and Prospect (2017-2030)
        1.5.7 Middle East and Africa Non-Alcoholic Steatohepatitis Treatment Market Size and Prospect (2017-2030)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 Non-Alcoholic Steatohepatitis Treatment Market Drivers
        1.6.2 Non-Alcoholic Steatohepatitis Treatment Market Restraints
        1.6.3 Non-Alcoholic Steatohepatitis Treatment Trends Analysis
2 Company Profiles
    2.1 Intercept Pharmaceuticals
        2.1.1 Intercept Pharmaceuticals Details
        2.1.2 Intercept Pharmaceuticals Major Business
        2.1.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis Treatment Product and Solutions
        2.1.4 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021,2022 and 2023)
        2.1.5 Intercept Pharmaceuticals Recent Developments and Future Plans
    2.2 Galmed Pharmaceuticals
        2.2.1 Galmed Pharmaceuticals Details
        2.2.2 Galmed Pharmaceuticals Major Business
        2.2.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Treatment Product and Solutions
        2.2.4 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021,2022 and 2023)
        2.2.5 Galmed Pharmaceuticals Recent Developments and Future Plans
    2.3 Inventiva Pharma
        2.3.1 Inventiva Pharma Details
        2.3.2 Inventiva Pharma Major Business
        2.3.3 Inventiva Pharma Non-Alcoholic Steatohepatitis Treatment Product and Solutions
        2.3.4 Inventiva Pharma Non-Alcoholic Steatohepatitis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021,2022 and 2023)
        2.3.5 Inventiva Pharma Recent Developments and Future Plans
    2.4 AbbVie Inc.
        2.4.1 AbbVie Inc. Details
        2.4.2 AbbVie Inc. Major Business
        2.4.3 AbbVie Inc. Non-Alcoholic Steatohepatitis Treatment Product and Solutions
        2.4.4 AbbVie Inc. Non-Alcoholic Steatohepatitis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021,2022 and 2023)
        2.4.5 AbbVie Inc. Recent Developments and Future Plans
    2.5 Galectin Therapeutics Inc.
        2.5.1 Galectin Therapeutics Inc. Details
        2.5.2 Galectin Therapeutics Inc. Major Business
        2.5.3 Galectin Therapeutics Inc. Non-Alcoholic Steatohepatitis Treatment Product and Solutions
        2.5.4 Galectin Therapeutics Inc. Non-Alcoholic Steatohepatitis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021,2022 and 2023)
        2.5.5 Galectin Therapeutics Inc. Recent Developments and Future Plans
    2.6 Madrigal Pharmaceuticals
        2.6.1 Madrigal Pharmaceuticals Details
        2.6.2 Madrigal Pharmaceuticals Major Business
        2.6.3 Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Treatment Product and Solutions
        2.6.4 Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021,2022 and 2023)
        2.6.5 Madrigal Pharmaceuticals Recent Developments and Future Plans
    2.7 NGM Biopharmaceuticals Inc.
        2.7.1 NGM Biopharmaceuticals Inc. Details
        2.7.2 NGM Biopharmaceuticals Inc. Major Business
        2.7.3 NGM Biopharmaceuticals Inc. Non-Alcoholic Steatohepatitis Treatment Product and Solutions
        2.7.4 NGM Biopharmaceuticals Inc. Non-Alcoholic Steatohepatitis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021,2022 and 2023)
        2.7.5 NGM Biopharmaceuticals Inc. Recent Developments and Future Plans
    2.8 Novo Nordisk A/S
        2.8.1 Novo Nordisk A/S Details
        2.8.2 Novo Nordisk A/S Major Business
        2.8.3 Novo Nordisk A/S Non-Alcoholic Steatohepatitis Treatment Product and Solutions
        2.8.4 Novo Nordisk A/S Non-Alcoholic Steatohepatitis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021,2022 and 2023)
        2.8.5 Novo Nordisk A/S Recent Developments and Future Plans
    2.9 Bristol Myers Squibb
        2.9.1 Bristol Myers Squibb Details
        2.9.2 Bristol Myers Squibb Major Business
        2.9.3 Bristol Myers Squibb Non-Alcoholic Steatohepatitis Treatment Product and Solutions
        2.9.4 Bristol Myers Squibb Non-Alcoholic Steatohepatitis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021,2022 and 2023)
        2.9.5 Bristol Myers Squibb Recent Developments and Future Plans
    2.10 Gilead Sciences Inc. 
        2.10.1 Gilead Sciences Inc. Details
        2.10.2 Gilead Sciences Inc. Major Business
        2.10.3 Gilead Sciences Inc. Non-Alcoholic Steatohepatitis Treatment Product and Solutions
        2.10.4 Gilead Sciences Inc. Non-Alcoholic Steatohepatitis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021,2022 and 2023)
        2.10.5 Gilead Sciences Inc. Recent Developments and Future Plans
3 Market Competition, by Players
    3.1 South Korea Non-Alcoholic Steatohepatitis Treatment Revenue and Share by Players (2019, 2020, 2021,2022 and 2023)
    3.2 Market Concentration Rate
        3.2.1 Top 3 Non-Alcoholic Steatohepatitis Treatment Players Market Share in 2022
        3.2.2 Top 10 Non-Alcoholic Steatohepatitis Treatment Players Market Share in 2022
        3.2.3 Market Competition Trend
    3.3 Non-Alcoholic Steatohepatitis Treatment Players Head Office, Products and Services Provided
    3.4 Non-Alcoholic Steatohepatitis Treatment Mergers & Acquisitions
    3.5 Non-Alcoholic Steatohepatitis Treatment New Entrants and Expansion Plans
4 Market Size Segment by Type
    4.1 South Korea Non-Alcoholic Steatohepatitis Treatment Revenue and Market Share by Type (2017-2022)
    4.2 South Korea Non-Alcoholic Steatohepatitis Treatment Market Forecast by Type (2023-2030)
5 Market Size Segment by Application
    5.1 South Korea Non-Alcoholic Steatohepatitis Treatment Revenue Market Share by Application (2017-2022)
    5.2 South Korea Non-Alcoholic Steatohepatitis Treatment Market Forecast by Application (2023-2030)
6 North America by Country, by Type, and by Application
    6.1 North America Non-Alcoholic Steatohepatitis Treatment Revenue by Type (2017-2030)
    6.2 North America Non-Alcoholic Steatohepatitis Treatment Revenue by Application (2017-2030)
    6.3 North America Non-Alcoholic Steatohepatitis Treatment Market Size by Country
        6.3.1 North America Non-Alcoholic Steatohepatitis Treatment Revenue by Country (2017-2030)
        6.3.2 United States Non-Alcoholic Steatohepatitis Treatment Market Size and Forecast (2017-2030)
        6.3.3 Canada Non-Alcoholic Steatohepatitis Treatment Market Size and Forecast (2017-2030)
        6.3.4 Mexico Non-Alcoholic Steatohepatitis Treatment Market Size and Forecast (2017-2030)
7 Europe by Country, by Type, and by Application
    7.1 Europe Non-Alcoholic Steatohepatitis Treatment Revenue by Type (2017-2030)
    7.2 Europe Non-Alcoholic Steatohepatitis Treatment Revenue by Application (2017-2030)
    7.3 Europe Non-Alcoholic Steatohepatitis Treatment Market Size by Country
        7.3.1 Europe Non-Alcoholic Steatohepatitis Treatment Revenue by Country (2017-2030)
        7.3.2 Germany Non-Alcoholic Steatohepatitis Treatment Market Size and Forecast (2017-2030)
        7.3.3 France Non-Alcoholic Steatohepatitis Treatment Market Size and Forecast (2017-2030)
        7.3.4 United Kingdom Non-Alcoholic Steatohepatitis Treatment Market Size and Forecast (2017-2030)
        7.3.5 Russia Non-Alcoholic Steatohepatitis Treatment Market Size and Forecast (2017-2030)
        7.3.6 Italy Non-Alcoholic Steatohepatitis Treatment Market Size and Forecast (2017-2030)
8 Asia-Pacific by Region, by Type, and by Application
    8.1 Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Revenue by Type (2017-2030)
    8.2 Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Revenue by Application (2017-2030)
    8.3 Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market Size by Region
        8.3.1 Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Revenue by Region (2017-2030)
        8.3.2 China Non-Alcoholic Steatohepatitis Treatment Market Size and Forecast (2017-2030)
        8.3.3 Japan Non-Alcoholic Steatohepatitis Treatment Market Size and Forecast (2017-2030)
        8.3.4 South Korea Non-Alcoholic Steatohepatitis Treatment Market Size and Forecast (2017-2030)
        8.3.5 India Non-Alcoholic Steatohepatitis Treatment Market Size and Forecast (2017-2030)
        8.3.6 Southeast Asia Non-Alcoholic Steatohepatitis Treatment Market Size and Forecast (2017-2030)
        8.3.7 Australia Non-Alcoholic Steatohepatitis Treatment Market Size and Forecast (2017-2030)
9 South America by Country, by Type, and by Application
    9.1 South America Non-Alcoholic Steatohepatitis Treatment Revenue by Type (2017-2030)
    9.2 South America Non-Alcoholic Steatohepatitis Treatment Revenue by Application (2017-2030)
    9.3 South America Non-Alcoholic Steatohepatitis Treatment Market Size by Country
        9.3.1 South America Non-Alcoholic Steatohepatitis Treatment Revenue by Country (2017-2030)
        9.3.2 Brazil Non-Alcoholic Steatohepatitis Treatment Market Size and Forecast (2017-2030)
        9.3.3 Argentina Non-Alcoholic Steatohepatitis Treatment Market Size and Forecast (2017-2030)
10 Middle East & Africa by Country, by Type, and by Application
    10.1 Middle East & Africa Non-Alcoholic Steatohepatitis Treatment Revenue by Type (2017-2030)
    10.2 Middle East & Africa Non-Alcoholic Steatohepatitis Treatment Revenue by Application (2017-2030)
    10.3 Middle East & Africa Non-Alcoholic Steatohepatitis Treatment Market Size by Country
        10.3.1 Middle East & Africa Non-Alcoholic Steatohepatitis Treatment Revenue by Country (2017-2030)
        10.3.2 Turkey Non-Alcoholic Steatohepatitis Treatment Market Size and Forecast (2017-2030)
        10.3.3 Saudi Arabia Non-Alcoholic Steatohepatitis Treatment Market Size and Forecast (2017-2030)
        10.3.4 UAE Non-Alcoholic Steatohepatitis Treatment Market Size and Forecast (2017-2030)
11 Research Findings and Conclusion
12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

South Korea Non-Alcoholic Steatohepatitis Treatment Market 2023 by Company, Regions, Type and Application, Forecast to 2030

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?